Eucrates Biomedical Acquisition Corp. (EUCR)
Eucrates Biomedical Acquisition Corp. operates in the Shell Companies industry of the Financial Services sector, headquartered in New York City, NY, US. The stock last traded at $10.04, up 0.00% on the session, giving a market capitalisation of $42.2M. On trailing twelve-month figures it carries a trailing P/E of 5.40, a net margin of 0.0%. Its beta of -0.07 implies it has historically moved less than the broad market.
Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises. Specifically, it aims to find and acquire a company operating within the life sciences or broader healthcare sectors across North America and Europe. Established in 2020, this entity has its headquarters situated in New York, New York.
Eucrates Biomedical Acquisition Corp. is most often compared with the following Financial Services names: